ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "inflammatory arthritis and interleukins (IL)"

  • Abstract Number: 946 • 2013 ACR/ARHP Annual Meeting

    Interleukin-34 Regulates Angiogenesis and Cell Proliferation In Inflammatory Arthritis, This Effect Is Potentiated By Hypoxia

    Emese Balogh1, Mary Connolly1, Monika Biniecka1, Jennifer McCormick2, Douglas J. Veale3 and Ursula Fearon2, 1Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland

    Background/Purpose: Interleukin-34 (IL-34) is a cytokine implicated in macrophage differentiation, angiogenesis and osteoclastogenesis in inflammatory arthritis (IA). IA is characterized by synovial hypoxia, increased oxidative…
  • Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting

    Long-Term Safety of Canakinumab in Patients with Gouty Arthritis

    Alexander So1, Reike Alten2, H. Ralph Schumacher3, Mark Bloch4, Thomas Bardin5, Markus R. John6, Gerhard Krammer6, Jan Michael Nebesky6, Aiyang Tao7 and Naomi Schlesinger8, 1Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, 2Charité Univ Medicine, Berlin, Germany, 3Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Holdsworth House Medical Practice, Sydney, Australia, 5Rheumatology, Hôpital Lariboisière, Paris, France, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits.  CAN…
  • Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT

    T. Bardin1, A. So2, R. Alten3, M. Bloch4, M. R. John5, G. Krammer5, J. M. Nebesky5, A. Tao6 and N. Schlesinger7, 1Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 2Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, 3Charité Univ Medicine, Berlin, Germany, 4Holdsworth House Medical Practice, Sydney, Australia, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences